

1 **Alpha7 nicotinic acetylcholine receptor agonist PHA 568487**
2 **dampens inflammation in PBMCs from patients with newly**
3 **discovered coronary artery disease.**

4

5 Filip Mjörnstedt¹, Rebecka Wilhelmsson¹ M. Sc., Marcus Ulleryd¹ PhD, Maria Hammarlund¹
6 PhD, Göran Bergström^{2,3}MD, PhD, Anders Gummesson^{2,4} MD, PhD, Maria E Johansson¹
7 PhD.

8 ¹Department of Physiology, Institute of Neuroscience and Physiology, and ²Department of
9 Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg
10 University, Gothenburg, Sweden

11 ³Department of Clinical Physiology and ⁴Department of Clinical Genetics and Genomics,
12 Sahlgrenska University Hospital, Västra Götalandsregionen, Gothenburg, Sweden.

13

14 **Word Count:** 997

15 **Keywords:** coronary artery disease, atherosclerosis, inflammation, alpha7 nicotinic
16 acetylcholine receptor.

17

18 **Correspondence**

19 Maria E. Johansson,

20 maria.e.johansson@neuro.gu.se

21 Department of Physiology

22 Institute of Neuroscience and Physiology

23 The Sahlgrenska Academy, University of Gothenburg,

24 Box 432, Gothenburg 405 30, Sweden

25 **Abstract**

26 **Background:** The $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ nAChR) controls inflammation
27 in experimental models. The $\alpha 7$ nAChR is expressed in human peripheral blood mononuclear
28 cells (PBMCs) as well as in human atherosclerotic plaques, yet, its role in regulating
29 inflammation in patients with cardiovascular disease remains unknown. In this study we aim
30 to investigate whether stimulation of the $\alpha 7$ nAChR can dampen the immune response in
31 patients with newly discovered coronary artery disease (CAD).

32 **Methods:** Human peripheral blood mononuclear cells (PBMCs) extracted from patients with
33 verified CAD (n=38) and control participants with healthy vessels (n=38) were challenged in
34 vitro with lipopolysaccharide (LPS) in combination with $\alpha 7$ nAChR agonist PHA 568487.
35 Supernatants were analyzed for cytokines using multiplex immunoassay. The CAD group
36 was re-examined after 6 months.

37 **Results:** $\alpha 7$ nAChR stimulation decreased TNF- α in all groups, in control participants and in
38 CAD patients, both at the first visit as well as the follow-up visit after 6 months. The most
39 pronounced effect of $\alpha 7$ nAChR stimulation was seen in CAD patients at their first visit,
40 where 12 of 17 cytokines were decreased (TNF- α , IL-1 β , IL-2, IL-4, IL-5, IL-7, IL-10, IL-
41 17A, GM-CSF, MCP-1, MIP-1 β and IL12(p70)).

42 **Conclusions:** Stimulation of $\alpha 7$ nAChR dampens the inflammatory response in human
43 PBMCs. This suggests that the anti-inflammatory properties of the $\alpha 7$ nAChR may have a role
44 in treating CAD.

45

46 **Introduction**

47 Signalling via the alpha7 nicotinic acetylcholine receptor ($\alpha 7$ nAChR) can regulate
48 inflammation. Following activation of the cholinergic anti-inflammatory pathway, or via
49 direct stimulation with agonists, the $\alpha 7$ nAChR can suppress the release of pro-inflammatory
50 cytokines from immune cells¹. In humans, the $\alpha 7$ nAChR is expressed both in peripheral
51 blood mononuclear cells (PBMCs)² and in atherosclerotic plaques³. Stimulation of the
52 $\alpha 7$ nAChR reduces the inflammatory response in whole blood from healthy donors⁴.
53 However, it is unclear whether stimulation of $\alpha 7$ nAChR can affect the inflammatory response
54 in patients with coronary artery disease (CAD). This study aims to investigate the impact of
55 $\alpha 7$ nAChR stimulation, using the selective agonist PHA548687, on the immune response in
56 PBMCs from both healthy individuals and patients with newly discovered CAD.

57

58 **Methods**

59 A total of 38 patients with extensive coronary atherosclerosis (CAD) and 38
60 participants with no atherosclerosis (Controls) were recruited from The Swedish
61 CardioPulmonary BioImage Study (SCAPIS)⁵. The study protocol was approved by
62 the ethical review board in Gothenburg, Sweden and informed consent was obtained
63 from all participants. Inclusion-criteria for CAD: three or more of the central segments
64 5, 6, 7, 1 or 11 having atherosclerosis or one of these segments with significant
65 stenosis (>50%). When calcium blooming was present, the level of stenosis was set to
66 1-49%. Inclusion-criteria for controls: no signs of coronary atherosclerosis (negative
67 CCTA and CAC scan). Exclusion criteria: History of myocardial infarction and/or
68 angina pectoris or any symptoms of angina pectoris. Pharmacological treatment with
69 statins within last 12 months. Any major surgical procedure or trauma within 4 weeks
70 of the first study visit.

71 During the first study visit (CAD1), the CAD group met with a study physician,
72 received lifestyle advice, and were recommended lipid-lowering statins to reduce the risk of
73 future cardiovascular events. The CAD group was invited to a second visit (CAD2) six
74 months later while the control group only attended one visit. Blood samples were drawn
75 during the visits for biochemical analysis and PBMC extraction.

76 For the in vitro stimulations, PBMCs were seeded at a concentration of 2×10^5
77 cells/well in triplicates and stimulated with LPS (8.33 ng/ml, List Biological Laboratories
78 Inc., Campbell, USA) with/without $\alpha 7nAChR$ agonist PHA568487 (83 μM) for 4 hours as
79 previously described². Supernatants were analyzed using the Bio-Plex Pro Human Cytokine
80 Panel 17-plex assay (Bio Rad Laboratories, Inc. Hercules, USA) following the
81 manufacturer's protocol. Inclusion criteria for each participant: Following LPS stimulation,

82 TNF response > 200 pg/ml and 10 times higher compared to unstimulated controls receiving
83 PBS. PBMC viability after stimulation with PHA568487 was determined using alamarBlue
84 Cell Viability Reagent (Invitrogen, Waltham, MA, USA) according to the manufacturer's
85 protocol. Two doses of PHA568487 (10 μ M or 100 μ M) were tested in human PBMCs
86 obtained from healthy volunteers (blood bank Sahlgrenska University Hospital, n=4) and
87 viability was measured after 24 h. No effect on viability was observed (data not shown).

88 Data were tested for normality with Shapiro Wilk's test and statistical methods
89 chosen accordingly. Population characteristics were analysed using one-way ANOVA
90 followed by Sidak's multiple comparison test. Cytokine data was analysed using one-
91 way ANOVA mixed-effect analysis with Geisser-Greenhouse correction, followed by
92 Holm-Sidak's multiple comparison test. A significance level of $p < 0.05$ was used.
93 Differences in sample numbers were due to lack of sample material or lack of LPS
94 response. The statistical analyses were conducted using GraphPad Prism software (La
95 Jolla, USA) and IBM SPSS Statistics (NY, USA).

96

97 **Results**

98 Statin treatment reduced cholesterol and LDL levels in CAD2 (Figure 1A). Among the three
99 groups, only one cytokine, TNF, was significantly reduced (Figure 1B-D). In Controls the
100 $\alpha 7nAChR$ agonist PHA568487 reduced TNF levels while IL-6 levels were increased (Figure
101 1B). In CAD1, PHA568487 reduced the concentration of 12 out of the 17 cytokines analyzed
102 (Figure 1C) whereas in CAD2, only TNF was reduced after PHA568487 treatment (Figure 1D).
103 When dividing the CAD2 group into the two treatment categories, statin and lifestyle advice
104 (n=20) versus lifestyle advice only (n=9), PHA568487 decreased the concentration of five
105 cytokines in PBMCs from patients receiving lifestyle advice only (Fig. 1E). The LPS response
106 was similar in Controls, CAD1 and CAD2. Likewise, there was no difference when
107 comparing the LPS response of patients receiving lipid-lowering treatment and lifestyle
108 advice to those receiving lifestyle advice only.

109

110 **Discussion**

111 To the best of our knowledge, this is the first study to demonstrate a significant anti-
112 inflammatory effect of $\alpha 7$ nAChR stimulation on PBMCs from patients with newly
113 discovered CAD. The study also confirms previous anti-inflammatory effects of $\alpha 7$ nAChR
114 stimulation in whole blood from healthy controls⁴. Interestingly, after six months of statin
115 treatment, the anti-inflammatory effect of $\alpha 7$ nAChR stimulation was reduced. Furthermore,
116 patients receiving lifestyle advice had a greater anti-inflammatory effect of PHA56847
117 compared to patients receiving statins and lifestyle advice. These findings implicate that
118 statins influence the inflammatory response. Indeed, statins not only reduce LDL levels in
119 patients, but also inflammation by lowering the inflammatory biomarker hsCRP⁶.
120 Furthermore, statins can suppress cytokine secretion from PBMCs; in hyperlipidemic
121 patients, simvastatin treatment reduced secretion of IL-1 β from PBMCs⁷. Intriguingly, the
122 effect of $\alpha 7$ nAChR stimulation is diminished after statin treatment. This lack of effect may be
123 due to shared signaling pathways between the two, as both statins⁸ and $\alpha 7$ nAChR agonists⁹
124 have been suggested to exert their anti-inflammatory effects by reducing the activity of the
125 transcription factor nuclear factor- κ B. Another possibility is that statins could alter the
126 expression level of $\alpha 7$ nAChR⁹. Surprisingly, IL-6 was increased in Controls, which may be
127 explained by the fact that IL-6 is a pleiotropic cytokine that can both increase and reduce
128 inflammation¹⁰. A limitation of the current study is that some participants were excluded due
129 to low cell numbers from PBMC isolation or lack of LPS response, which prevented us from
130 conducting a paired t-test analysis. Despite this limitation, the number of participants in each
131 group was sufficient to identify significant differences.

132 In conclusion, stimulation of $\alpha 7$ nAChR with PHA56847 reduces the inflammatory
133 response of human PBMCs. This effect is more prominent in PBMCs from patients with

134 newly discovered CAD, demonstrating the potential of $\alpha 7$ nAChR's anti-inflammatory
135 properties in treating chronic inflammatory diseases such as CAD.

136

137 **Funding**

138 This work was supported by the Swedish Research Council, the Swedish Heart-Lung
139 Foundation, Mary von Sydow foundation, Stiftelsen Gamla tjänarinnor, Stiftelsen Tornspiran,
140 Dr. Felix Neuberghs Foundation, Wilhelm and Martina Lundgren foundation and Grants
141 from the Swedish state under the agreement between the Swedish government and the county
142 councils, the ALF-agreement (ALF GBG-723131).

143

144 **Disclosures**

145 None

146

147 **Data availability**

148 The participant-level datasets used for this report have been deposited with the Swedish
149 National Data Service (<https://snd.gu.se/>, a data repository certified by Core Trust Seal). Due
150 to patient consent and confidentiality agreements, the datasets can be made available for
151 validation purposes by contacting snd@snd.gu.se. Data access will be evaluated according to
152 Swedish legislation. Data access for research related questions in the program can be made
153 available by contacting the corresponding author.

154

155 **Figure Legend**

156 **Figure 1. Stimulation of the alpha7 nicotinic acetylcholine receptor ($\alpha 7$ nAChR) decreases**
157 **the inflammatory response in PBMCs from patients with newly discovered coronary artery**

158 **disease.** PBMCs were challenged with LPS (8.33 ng/ml) and co-treated with $\alpha 7$ nAChR agonist
159 PHA-568487 (83 μ M) for 4 hours. (A) Population characteristics. First panel from left;
160 distribution of women and men included in the study, numbers above bars shows exact numbers
161 of participants, second panel from left; age, weight (kg) and body mass index (BMI, kg/m^2), third
162 panel from left; systolic and diastolic blood pressure (SBP, DBP), fourth panel from left; glucose
163 (Glu), HbA1c, LDL and HDL (all in mmol/L), fifth panel from left C-reactive protein (CRP,
164 mg/L) and white blood cell (WBC, $10^9/\text{L}$). Data expressed as mean \pm SD. (B-E) Multiplex
165 analysis of cytokines IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, IL-17A,
166 G-CSF, GM-CSF, IFN γ , MCP-1, MIP-1 β and TNF in (B) Controls (n=25-26), (C) CAD visit 1
167 (CAD1, n=19-21), (D) CAD visit 2 (CAD2, n=28-29) and (E) CAD visit 2 showing PBMC
168 response from patients who only received life-style advice (CAD2-LS, n=9). Cytokine data
169 expressed as mean \pm SEM. Shaded areas highlights cytokines significantly decreased by
170 $\alpha 7$ nAChR agonist PHA568487. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

171

172


173

174


175 **References**

- 176 1. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a
177 pharmacological target for inflammation. *Br J Pharmacol.* 2007;**151(7)**:915-29.
- 178 2. Pattanaik B, Hammarlund M, Mjörnstedt F, Ulleryd MA, Zhong W, Uhlén M, et al.
179 Polymorphisms in alpha 7 nicotinic acetylcholine receptor gene, CHRNA7, and its partially
180 duplicated gene, CHRFAM7A, associate with increased inflammatory response in human
181 peripheral mononuclear cells. *FASEB journal : official publication of the Federation of*
182 *American Societies for Experimental Biology.* 2022;**36(5)**:e22271.
- 183 3. Johansson ME, Ulleryd MA, Bernardi A, Lundberg AM, Andersson A, Folkersen L,
184 et al. $\alpha 7$ Nicotinic acetylcholine receptor is expressed in human atherosclerosis and inhibits
185 disease in mice--brief report. *Arteriosclerosis, thrombosis, and vascular biology.*
186 2014;**34(12)**:2632-6.
- 187 4. Ulleryd MA, Mjornstedt F, Panagaki D, Yang LJ, Engevall K, Gutierrez S, et al.
188 Stimulation of alpha 7 nicotinic acetylcholine receptor (alpha7nAChR) inhibits
189 atherosclerosis via immunomodulatory effects on myeloid cells. *Atherosclerosis.*
190 2019;**287**:122-33.
- 191 5. Bergström G, Persson M, Adiels M, Björnson E, Bonander C, Ahlström H, et al.
192 Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population.
193 *Circulation.* 2021;**144(12)**:916-29.
- 194 6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al.
195 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after
196 initiation of rosuvastatin: a prospective study of the JUPITER trial. *The Lancet.*
197 2009;**373(9670)**:1175-82.
- 198 7. Boland AJ, Gangadharan N, Kavanagh P, Hemeryck L, Kieran J, Barry M, et al.
199 Simvastatin Suppresses Interleukin I β Release in Human Peripheral Blood Mononuclear
200 Cells Stimulated With Cholesterol Crystals. *Journal of Cardiovascular Pharmacology and*
201 *Therapeutics.* 2018;**23(6)**:509-17.
- 202 8. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J.
203 Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth
204 muscle cells and mononuclear cells. *Atherosclerosis.* 1999;**147(2)**:253-61.
- 205 9. Xu H, Shi Q, Mo Y, Wu L, Gu J, Xu Y. Downregulation of $\alpha 7$ nicotinic acetylcholine
206 receptors in peripheral blood monocytes is associated with enhanced inflammation in
207 preeclampsia. *BMC Pregnancy and Childbirth.* 2019;**19(1)**.
- 208 10. Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, et al. Response to
209 IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to
210 gp130 expression: fusing experimental insights and dynamic modelling. *Cell Commun*
211 *Signal.* 2019;**17(1)**:46.
212


Study Population



Methods



Results



Graphical Abstract created with BioRender.com

